Ionis Pharmaceuticals Inc (IONS) Director B Lynne Parshall Sells 8,334 Shares
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director B Lynne Parshall sold 8,334 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $75.00, for a total value of $625,050.00. Following the completion of the sale, the director now owns 61,011 shares of the company’s stock, valued at $4,575,825. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
B Lynne Parshall also recently made the following trade(s):
- On Wednesday, February 27th, B Lynne Parshall sold 8,333 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $70.00, for a total value of $583,310.00.
IONS stock traded up $0.83 during midday trading on Thursday, reaching $77.44. The company’s stock had a trading volume of 1,223,900 shares, compared to its average volume of 989,482. The company has a quick ratio of 7.85, a current ratio of 7.88 and a debt-to-equity ratio of 0.53. Ionis Pharmaceuticals Inc has a 1 year low of $39.07 and a 1 year high of $78.20. The firm has a market cap of $10.60 billion, a price-to-earnings ratio of 26.16 and a beta of 2.40.
A number of analysts recently issued reports on the company. Piper Jaffray Companies raised their price target on Ionis Pharmaceuticals to $60.00 and gave the stock a “neutral” rating in a research report on Thursday, February 28th. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Thursday, December 6th. ValuEngine upgraded Ionis Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 28th. BMO Capital Markets raised their price target on Ionis Pharmaceuticals from $70.00 to $82.00 and gave the stock an “outperform” rating in a research report on Thursday, February 28th. Finally, Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $60.57.
Hedge funds have recently added to or reduced their stakes in the business. Huntington National Bank boosted its holdings in Ionis Pharmaceuticals by 159.3% in the fourth quarter. Huntington National Bank now owns 638 shares of the company’s stock worth $34,000 after acquiring an additional 392 shares in the last quarter. Essex Savings Bank purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $39,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $43,000. Daiwa Securities Group Inc. increased its position in shares of Ionis Pharmaceuticals by 29.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 890 shares of the company’s stock valued at $48,000 after buying an additional 200 shares in the last quarter. Finally, Portfolio Solutions LLC purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $54,000. Institutional investors and hedge funds own 84.84% of the company’s stock.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Featured Article: Percentage Decliners
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.